中国临床药理学杂志2018，Vol.34Issue(8)：934-937,4.DOI:10.13699/j.cnki.1001-6821.2018.08.006
依帕司他片联合前列地尔注射剂治疗糖尿病视网膜病变的临床研究
Clinical research of epalrestat tablet in combination with alprostadil injection in the treatment diabetic retinopathy
摘要
Abstract
Objective To observe the clinical efficacy and safety profile of epalrestat tablet in combination with alprostadil injection in the treatment of diabetic retinopathy.Methods A total of 92 patients with diabetic retinopathy were randomly divided into the treatment group (n =46) and the control group (n =46).The control group was treated with intravenous drip of alprostadil injection at dose of 5 μg,once daily.The treatment group received oral administration of epalrestat at dose of 50 mg,three times daily.Both groups were treated for 14 d.Clinical efficacy,superoxide dismutase (SOD),total antioxidant capacity (TAOC),tumor necrosis factor-α (TNF-α),blood glucose indicators,and adverse drug reactions between two group was compared between the two groups.Results The total effective rates of the treatment group and control group were 95.65％ (44 cases/46 cases) and 78.26％ (36 cases/46 cases),respectively,and the difference was statistically significant (P ＜0.05).There were significant differences between the treatment group and the control group in the levels of SOD [(88.59 ± 11.02) vs (80.83 ± 10.68)IU · mL-1],TAOC [(20.44±2.25) vs (15.41 ±2.01)IU · mL-1],TNF-α [(11.72±1.55) vs (17.35 ±1.87) ng· L-1],fasting blood glucose [(5.05 ± 0.71) vs (5.92 ± 0.65) mmol · L-1],postprandial blood glucose [(8.20 ± 0.76),(8.80 ± 1.15)mmol · L-1],glycated hemoglobin [(6.17 ±0.85)％ vs (6.77 ±0.82)％] (P ＜0.05).There were no adverse drug reactions in the two groups.Conclusion epalrestat in combination with alprostadil was effective and safe in treating diabetic retinopathy.关键词
依帕司他片/前列地尔注射剂/糖尿病视网膜病变/超氧化物歧化酶/总抗氧化能力/肿瘤坏死因子-αKey words
epalrestat tablet/alprostadil injection/diabetic retinopathy/superoxide dismutase/total antioxidant capacity/tumor necrosis factor-α分类
医药卫生引用本文复制引用
肖巍,马雅娟,陈林秀,高建波..依帕司他片联合前列地尔注射剂治疗糖尿病视网膜病变的临床研究[J].中国临床药理学杂志,2018,34(8):934-937,4.基金项目
嘉兴市科技计划基金资助项目(2015AY23055) （2015AY23055）
